Cargando…
MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Somatic mutations in TP53 are seen in many human cancers. In addition, the protein product of the wild-type TP53 can be sequestered by the protein MDM2 (murine double minute 2). This protein is commonly overexpressed in human sarcomas and gliomas, usually as a result of gene amplification. In this s...
Autores principales: | Foulkes, W. D., Stamp, G. W., Afzal, S., Lalani, N., McFarlane, C. P., Trowsdale, J., Campbell, I. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034047/ https://www.ncbi.nlm.nih.gov/pubmed/7547235 |
Ejemplares similares
-
Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer.
por: Foulkes, W. D., et al.
Publicado: (1993) -
MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014) -
Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma.
por: Foulkes, W. D., et al.
Publicado: (1993) -
MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014) -
Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)